Cellares

Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy developer and manufacturer Cellares to produce a CAR-T cell therapy. This collaboration will utilize Cellares’ clinical and commercial-stage manufacturing platform following a proof-of-concept technology transfer, which is expected to be completed within months. Advantages of…